GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tactile Systems Technology Inc (NAS:TCMD) » Definitions » 5-Year RORE %

TCMD (Tactile Systems Technology) 5-Year RORE % : 662.65% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tactile Systems Technology 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Tactile Systems Technology's 5-Year RORE % for the quarter that ended in Sep. 2024 was 662.65%.

The industry rank for Tactile Systems Technology's 5-Year RORE % or its related term are showing as below:

TCMD's 5-Year RORE % is ranked better than
99.11% of 671 companies
in the Medical Devices & Instruments industry
Industry Median: -4.02 vs TCMD: 662.65

Tactile Systems Technology 5-Year RORE % Historical Data

The historical data trend for Tactile Systems Technology's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tactile Systems Technology 5-Year RORE % Chart

Tactile Systems Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.97 -9.27 -167.60 187.90 308.74

Tactile Systems Technology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,566.67 308.74 2,183.33 2,407.89 662.65

Competitive Comparison of Tactile Systems Technology's 5-Year RORE %

For the Medical Devices subindustry, Tactile Systems Technology's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tactile Systems Technology's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tactile Systems Technology's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Tactile Systems Technology's 5-Year RORE % falls into.



Tactile Systems Technology 5-Year RORE % Calculation

Tactile Systems Technology's 5-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 0.65--0.45 )/( 0.166-0 )
=1.1/0.166
=662.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 5-year before.


Tactile Systems Technology  (NAS:TCMD) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Tactile Systems Technology 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Tactile Systems Technology's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tactile Systems Technology Business Description

Traded in Other Exchanges
Address
3701 Wayzata Boulevard, Suite 300, Minneapolis, MN, USA, 55416
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Executives
Sherri Lee Ferstler officer: Senior VP, Sales 1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
Elaine M. Birkemeyer officer: Chief Financial Officer 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
William W Burke director 3868 MOCKINGBIRD LN, DALLAS TX 75205
Kristie Burns officer: Sr. VP Mktg & Clinical Affairs 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Daniel L. Reuvers director, officer: President and CEO INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Boyd Vindell Washington director 1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
Eric Pauls officer: Senior VP, Sales 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Brent Moen officer: Chief Financial Officer 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Valerie L. Asbury director 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Bryan Rishe officer: Vice President, Sales 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Sheri Louise Dodd director 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Deepti Jain director 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Gerald R. Mattys director, officer: Chief Executive Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413